针对非肌肉侵入性膀癌的新型静脉输送系统
Alessandro Uleri1, Olga Katzendorn1, Zine Eddine Khene2
1Department of Urology UROSUD, La Croix du Sud Hospital, Quint Fonsegrives.
Current opinion in urology
|July 17, 2025
概括
新型静脉输送系统在治疗非肌肉侵入性膀癌 (NMIBC) 方面表现有前途. 这些先进的治疗方法改善了药物输送和患者的结果,为传统疗法提供了替代方案.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 药物输送系统 药物输送系统
背景情况:
- 非肌肉侵入性膀癌 (NMIBC) 占诊断病例的75%.
- 高的复发率和进展率带来了管理挑战.
- 目前的静脉内疗法在药物输送和副作用方面存在局限性.
研究的目的:
- 审查NMIBC的新型静脉输送系统.
- 评估旨在克服传统疗法的局限性而设计的系统.
- 评估瘤治疗结果的潜在改善.
主要方法:
- 对NMIBC的创新性静脉输送系统的审查.
- 系统的评估,包括高热体内化学疗法 (HIVEC).
- 对静脉药物释放系统 (iDRS) 和其他新型药物的评估.
主要成果:
- 在高风险NMIBC中,HIVEC显示出有效性.
- 像TAR-200这样的iDRS在BCG不响应的疾病中实现了84%的完整反应.
- 在特定的NMIBC亚型中,UGN-102和Oncofid-P-B显示出显著的响应率.
结论:
- 新型系统增强药物保留和组织透,可能减少不良事件.
- 这些方法为选定的NMIBC患者提供了有希望的替代方案.
- 对于这些先进的治疗方法,正在进行的临床验证正在等待.
相关概念视频
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...